XML 137 R91.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Information (Reconciliation Of Segment Income From Operations To Income Before Income Taxes) (Detail) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]                      
Income from operations $ 2,017 $ 1,403 $ 1,711 $ 440 $ 1,168 $ 1,577 $ 982 $ 291 $ 5,571 $ 4,018 $ 2,386
Net interest and other financial costs                 1,003 674 564
Income before income taxes                 4,568 3,344 1,822
Operating Segments                      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]                      
Income from operations                 6,261 4,389 3,138
Corporate and Other                      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]                      
Income from operations                 (502) (365) [1] (266)
Segment Reconciling Items                      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]                      
Transaction-related costs                 (197) 0 0
Litigation                 0 (29) 0
Impairment [2]                 $ 9 $ 23 $ (486)
[1] Corporate and other unallocated items consists primarily of MPC’s corporate administrative expenses and costs related to certain non-operating assets, except for corporate overhead expenses attributable to MPLX and ANDX, which are included in the Midstream segment. Corporate overhead expenses are not allocated to the Refining & Marketing and Retail segments.
[2] 2017 includes MPC’s share of gains from the the sale of assets remaining from the canceled Sandpiper pipeline project. 2016 includes impairments of goodwill and equity method investments. See Note 17.